ASAM Issues First National Clinical Guide for Medetomidine
The American Society of Addiction Medicine released the first clinical guide and national resource for managing the intoxication and withdrawal of medetomidine, Psychiatric Times reported.
Medetomidine, a veterinary sedative never approved for human use, has infiltrated the unregulated opioid supply and brings unique, severe clinical symptoms. Patients experiencing intoxication show persistent sedation and bradycardia, while withdrawal develops rapidly with extreme tachycardia and elevated blood pressure that typical addiction medications fail to ease.
Medetomidine withdrawal requires frequent critical care escalation
Because withdrawal symptoms can rapidly become life-threatening, patients presenting to hospitals with severe medetomidine withdrawal require escalation to critical care more frequently than those undergoing standard opioid withdrawal.
Addiction treatment professionals on the front lines face a debilitating crisis as the adulterant spreads across the country, according to Stephen M. Taylor, president of the American Society of Addiction Medicine, who told Psychiatric Times that emergency medicine and addiction care teams must learn to properly identify and treat exposed patients.
“The unpredictable illicit drug supply continues to pose a significant health risk to people and communities across America,” said Stephen M. Taylor, president of the American Society of Addiction Medicine.
In Philadelphia, emergency room doctors began raising alarms about opioid users experiencing severe withdrawal who failed to respond to usual symptom-easing medications, Inquirer.com reported. Local health officials identified medetomidine as the culprit after learning lessons from the city’s earlier infiltration of xylazine, another animal tranquilizer known on the street as tranq, which spurred extreme withdrawal symptoms and severe skin wounds leading to amputations.
Doctors seek specific diagnostic codes to improve care
The lack of specific diagnostic codes previously forced doctors to cobble together other diagnoses on patient charts to document symptoms, according to Inquirer.com. Daniel Teixeira da Silva, director of the Philadelphia health department’s Division of Substance Use Prevention and Harm Reduction, told Inquirer.com that the goal of tracking is to improve care for people who use drugs.
“The goal of this is to be one part of the effort to improve care for people who use drugs,” said Daniel Teixeira da Silva, director of the Philadelphia health department's Division of Substance Use Prevention and Harm Reduction.
The Centers for Disease Control and Prevention instituted a specific ICD code for medetomidine toxicity on Oct. 1, allowing doctors across the country to track the condition in patient records and medical billing, Inquirer.com reported. By this date next year, the CDC will institute a second ICD code specifically for medetomidine withdrawal, providing public health officials with standardized tools to log patient trends in real time.
Patients arrive critically ill requiring intensive monitoring
Local addiction treatment providers like Phil Durney, inpatient medical director of Jefferson’s addiction consult service, told Inquirer.com that the same patient cohort continues coming to the hospital but arrives critically ill, requiring intravenous medication and intensive monitoring for dangerous blood pressure and heart rate shifts.
Local addiction treatment providers have considered advocating for a catch-all ICD code to track withdrawal from new psychoactive substances broadly. London, an addiction treatment provider cited by Inquirer.com, noted that treatment professionals harbor little confidence that the problem will vanish, stating that the long-term outlook remains focused on anticipating the next emerging adulterant in the illicit drug supply.
Common Questions on Medetomidine Protocol
What are the primary signs of medetomidine intoxication?
Medetomidine intoxication is associated with persistent sedation and bradycardia, presenting distinct clinical challenges compared to traditional opioids. These symptoms emerge as the veterinary sedative contaminates the unregulated opioid supply.
How does medetomidine withdrawal differ from standard opioid withdrawal?
Medetomidine withdrawal develops rapidly and causes severe symptoms, including extreme tachycardia and elevated blood pressure, that do not respond to typical medications used to manage withdrawal from other substances.
When did national medical coding for medetomidine take effect?
The Centers for Disease Control and Prevention instituted an ICD code for medetomidine toxicity on Oct. 1, with a corresponding code for medetomidine withdrawal scheduled to launch by the same date next year, according to Inquirer.com.